News
CDXC
3.930
-1.01%
-0.040
Weekly Report: what happened at CDXC last week (0408-0412)?
Weekly Report · 3d ago
ChromaDex Price Target Raised to $6.00/Share From $4.25 by Roth MKM
Dow Jones · 04/09 14:10
ChromaDex Is Maintained at Buy by Roth MKM
Dow Jones · 04/09 14:10
Roth MKM Maintains Buy on ChromaDex, Raises Price Target to $6
Benzinga · 04/09 13:59
Weekly Report: what happened at CDXC last week (0401-0405)?
Weekly Report · 04/08 12:06
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
NASDAQ · 04/02 10:48
Weekly Report: what happened at CDXC last week (0325-0329)?
Weekly Report · 04/01 12:02
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
ChromaDex Corp. Announces its flagship Tru Niagen product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program. AlkeMist Labs is a leading testing laboratory known for its rigorous herbal and dietary supplement analysis. The company is the number one healthy-aging NAD+ supplement company in the United States. TruNiagen features the most efficient, patented, superior quality NAD+ precursor on the market.
Barchart · 03/26 07:32
Weekly Report: what happened at CDXC last week (0318-0322)?
Weekly Report · 03/25 12:06
12 Health Care Stocks Moving In Monday's Intraday Session
Fresh2 Group (NASDAQ:FRES) shares rose 41.7% to $0.66 during Monday's regular session. Akso Health Group stock moved upwards by 29.0%. ChromaDex stock rose upwards by 27.91%. Trxade Health shares declined by 33.0% during the session.
Benzinga · 03/18 17:31
Weekly Report: what happened at CDXC last week (0311-0315)?
Weekly Report · 03/18 12:04
Weekly Report: what happened at CDXC last week (0304-0308)?
Weekly Report · 03/11 11:59
ChromaDex Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/11 11:33
ChromaDex Price Target Raised to $6.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 03/11 11:33
HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $6
Benzinga · 03/11 11:23
CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023
ChromaDex just reported results for the fourth quarter of 2023. The company did not report any EPS for the quarter. ChromaDex reported revenue of $21.20 million. This was 1.03% better than the analyst estimate of $20.98 million.
Investorplace · 03/07 02:53
Chromadex Releases Insightful Corporate Presentation Online
TipRanks · 03/06 21:13
Press Release: ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results. Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year.
Dow Jones · 03/06 21:04
*ChromaDex 4Q Loss/Shr 2c >CDXC
Dow Jones · 03/06 21:04
Press Release: ChromaDex Corporation Reports -3-
The company expects to report a net loss of $1.9 million for the first quarter of 2022. The Company expects to earn $1,000 million in the second quarter. The company has a target for Adjusted EBITDA of $2.5 million. The Company has a long-term target of $10 million. The stock price of the company is expected to rise to $20.
Dow Jones · 03/06 21:04
More
Webull provides a variety of real-time CDXC stock news. You can receive the latest news about Chromadex Corp through multiple platforms. This information may help you make smarter investment decisions.
About CDXC
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.